Articles By Jack Cush, MD
Is DLCO Predictive in Rheumatoid Interstitial Lung Disease?
Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA). Its presence may portend grave outcomes for those affected. The prevalence of ILD in RA ranges from 7.7% to 44% depending on the assessment tools used.
Read Article
Healthcare Consumer Engagement Increasing
Deloitte published its 2015 Healthcare Consumer Survey to examine online resource and technology use by patients. This is important, as the health care industry has expanded the development of online information resources, mobile applications, and personal health devices.
Read Article
Hip Fractures Increased in Rheumatoid Arthritis
An analysis of 741,589 patients over age 45 years from southern Swedish registry examined patients who were followed (between 1998 and 2012) until a hip fracture, death or exit from the region occurred.
Read Article
Lupus Foundation of America Announces 2015 Award Recipients
Healio reported the newly announced grant recipients from the Lupus Foundation of America.
Read Article
Diffuse Alveolar Hemorrhage in Lupus Reviewed
Diffuse alveolar hemorrhage (DAH) is a rare but catastrophic complication of systemic lupus erythematosus. Presentations are usually acute and the potential for significant morbidity and mortality risk mandates early diagnosis and aggressive interventions.
Read Article
Angiogenic Biomarkers Predict Adverse Outcomes Pregnancies in Lupus
The PROMISSE (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study has revealed several important lessons in lupus care.
Read Article
Strange ICD-10 Codes
The range of categories and diagnostic possibilities is astronomical with the new ICD-10 and its 68,000 codes.
Read Article
Top 5 and Bottom 5 Clinic Tools
Rheums do not live by wits and cytokine blockers alone. We need tools, equipment and material goods to be the diagnostician, communicator, and technical wizards that triple-threat rheumatologists propound to be. Not long ago I ranked my top and bottom 5 joints. Now we tackle the most and least important tools of the trade in rheumatology.
Read Article
Brodalumab vs. Ustekinumab: Head-to-Head Studies of Psoriasis
AMAGINE-2 and AMAGINE-3 are in two phase 3 studies that compare multiple doses of brodalumab (anti-IL-17) and ustekinumab (anti-12/23) in adults with moderate-to-severe psoriasis.
Read Article
Ustekinumab Effective in Adolescents with Psoriasis
Biologic and new drug development seldom targets children and adolescents. This study evaluated the efficacy and safety of ustekinumab in adolescents age 12 to 17 years with moderate-to-severe psoriasis,
Read Article
